Investors

Press Releases

Press Releases

Press Releases

Oct 13, 2021
Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit
WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will be giving multiple
PDF Version
Jul 12, 2021
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
Data demonstrate Kymera’s ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtypes with aberrant STAT3 activation Kymera anticipates IND submission for STAT3 degrader KT-333 in
PDF Version
Displaying 1 - 10 of 32

Investor Contact

Bruce Jacobs, CFA, MBA
Chief Financial Officer
investors@kymeratx.com

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com 
+ 1 339.970.2843
 

Media Contact

media@kymeratx.com

Tyler Gagnon
Director, Corporate Communications
tgagnon@kymeratx.com

Sign Up for Email Alerts